Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration Free

Abstract

The immunogenic properties of an E1-deleted, human adenovirus type 5 (Ad5) vaccine virus with activity against rabies were examined in mice, foxes and dogs using different routes of administration. NMRI mice received 10, 10, 10, 10 and 10 TCID by peroral or intramuscular (i.m.) administration. Furthermore, six mice received 10 TCID intracerebrally (i.c.). The construct elicited marked seroconversion in mice after oral administration. Immunoreactivity in mice was even more pronounced i.m. and i.c. After direct oral administration (10 TCID) in foxes, six of eight animals developed rabies virus-neutralizing antibodies (VNA). All foxes immunized by direct injection (10 TCID) in the membrane of the jejunum were shown to seroconvert. Pre-existing immunity against canine adenovirus did not hinder the development of rabies VNA after oral application of the construct (10 TCID). Fox cubs (24–29 days old) born from rabies-immune vixens were shown to develop very high levels of rabies VNA after i.m. administration (10 TCID), indicating that the immunogenicity of the construct could surpass maternally transferred immunity. In dogs, the construct (10 TCID) induced a very strong immune response after i.m. administration. However, no immune response was detectable in dogs after direct oral administration (10 TCID) or after endoscopic deposition in the smaller intestine (10 TCID). Hence, it must be concluded that the construct is not suitable for oral vaccination of dogs against rabies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-82-9-2191
2001-09-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/82/9/0822191a.html?itemId=/content/journal/jgv/10.1099/0022-1317-82-9-2191&mimeType=html&fmt=ahah

References

  1. Anonymous. 1978; WHO informal consultation on reference preparations and potency tests for rabies vaccines. Developments in Biological Standardization 40:265–271
    [Google Scholar]
  2. Berkner K. L., Sharp P. A. 1985; Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant. Nucleic Acids Research 13:841–857
    [Google Scholar]
  3. Charlton K. M., Artois M., Prevec L., Campbell J. B., Casey G. A., Wandeler A. I., Armstrong J. 1992; Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Archives of Virology 123:169–179
    [Google Scholar]
  4. Cox J. H., Schneider L. G. 1976; Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine. Journal of Clinical Microbiology 3:96–101
    [Google Scholar]
  5. Cypher B. L., Scrivner J. H., Hammer K. L., O’Farrell T. P. 1998; Viral antibodies in coyotes from California. Journal of Wildlife Diseases 34:259–264
    [Google Scholar]
  6. Dmitriev I., Kashentseva E., Rogers B. E., Krasnykh V., Curiel D. T. 2000; Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. Journal of Virology 74:6875–6884
    [Google Scholar]
  7. Döhner L., Hudemann H. 1972; Untersuchungen zur Kristallisation von Hexonen der Adenoviren der Gruppe III. Archiv für die gesamte Virusforschung 38279–289
    [Google Scholar]
  8. Fooks A. R., Jeevarajah D., Lee J., Warnes A., Niewiesk S., ter Meulen V., Stephenson J. R., Clegg J. C. S. 1998; Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. Journal of General Virology 79:1027–1031
    [Google Scholar]
  9. Garcelon D. K., Wayne R. K., Gonzales B. J. 1992; A serologic survey of the island fox ( Urocyon littoralis ) on the Channel Islands, California. Journal of Wildlife Diseases 28:223–229
    [Google Scholar]
  10. Gese E. M., Schultz R. D., Johnson M. R., Williams E. S., Crabtree R. L., Ruff R. L. 1997; Serological survey for diseases in free-ranging coyotes ( Canis latrans ) in Yellowstone National Park, Wyoming. Journal of Wildlife Diseases 33:47–56
    [Google Scholar]
  11. Hammond J. M., McCoy R. J., Jansen E. S., Morrissy C. J., Hodgson A. L. M., Johnson M. A. 2000; Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 18:1040–1050
    [Google Scholar]
  12. Klonjkowski B., Denesvre C., Eliot M. 1999; Adenoviral vectors for vaccines. In Adenoviruses: Basic Biology to Gene Therapy pp 163–173 Edited by Seth P. Austin, TX: Landes;
    [Google Scholar]
  13. Laurenson K., Van Heerden J., Stander P., Van Vuuren M. J. 1997; Seroepidemiological survey of sympatric domestic and wild dogs ( Lycaon pictus ) in Tsumkwe District, north-eastern Namibia. Onderstepoort Journal of Veterinary Research 64:313–316
    [Google Scholar]
  14. Mayr A., Bachmann P. A., Bibrack B., Wittmann G. 1977 Virologische Arbeitsmethoden Band II. Jena: Gustav Fischer;
  15. Monteil M., Le Pottier M. F., Ristov A. A., Cariolet R., L’Hospitalier R., Klonjkowski B., Eloit M. 2000; Single inoculation of replication-defective adenovirus-vectored vaccines at birth in piglets with maternal antibodies induces high level of antibodies and protection against pseudorabies. Vaccine 18:1738–1742
    [Google Scholar]
  16. Müller T., Schlüter H. 1998; Oral immunization of red foxes ( Vulpes vulpes L.) in Europe – a review. Journal of Etlik Veterinary Microbiology 9:35–59
    [Google Scholar]
  17. Müller T., Schuster P., Vos A., Selhorst T., Wenzel U., Neubert A. 2001; Effect of maternal immunity on the immune response of young foxes to oral vaccination against rabies with SAD B19. American Journal of Veterinary Research (in press)
    [Google Scholar]
  18. Neubert A., Schuster P., Müller T., Vos A., Pommerening E. 2001; Immunogenicity and efficacy of the oral rabies vaccine SAD B19 in foxes. Journal of Veterinary Medicine B 48:179–183
    [Google Scholar]
  19. Papp Z., Middleton D. M., Mittal S. K., Babiuk L. A., Baca-Estrada M. E. 1997; Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection. Journal of General Virology 78:2933–2943
    [Google Scholar]
  20. Prevec L., Campbell J. B., Christie B. S., Belbeck L., Graham F. L. 1990; A recombinant human adenovirus vaccine against rabies. Journal of Infectious Diseases 161:27–30
    [Google Scholar]
  21. Russell W. C. 2000; Update on adenovirus and its vectors. Journal of General Virology 81:2573–2604
    [Google Scholar]
  22. Schmidt M. R., Piekos B., Cabatingan M. S., Woodland R. T. 2000; Expression of a human coxsackie/adenovirus receptor transgene permits adenovirus infection of primary lymphocytes. Journal of Immunology 165:4112–4119
    [Google Scholar]
  23. Schneider L. G., Cox J. H. 1983; Ein Feldversuch zur oralen Immunisierung von Füchsen gegen die Tollwut in der Bundesrepublik Deutschland. I. Unschädlichkeit, Wirksamkeit und Stabilität der Vakzine SAD B19. Tierärztliche Umschau 38:315–324
    [Google Scholar]
  24. Schuster P., Müller T., Vos A., Selhorst T., Neubert L., Pommerening E. 2001; Comparative immunogenicity and efficacy studies with oral rabies vaccine SAD P5/88 in raccoon dogs and foxes. Acta Veterinaria Hungarica (in press)
    [Google Scholar]
  25. Smith J. S., Yager P. A., Baer G. M. 1973; A rapid reproducible test for determining rabies neutralizing antibody. Bulletin of the World Health Organization 48:535–541
    [Google Scholar]
  26. Spencer J. A., Bingham J., Heath R., Richards B. 1999; Presence of antibodies to canine distemper virus, canine parvovirus and canine adenovirus type 1 in free-ranging jackals ( Canis adustus and Canis mesomelas ) in Zimbabwe. Onderstepoort. Journal of Veterinary Research 66:251–253
    [Google Scholar]
  27. Stöhr K., Meslin F.-M. 1996; Progress and setbacks in the oral immunisation of foxes against rabies in Europe. Veterinary Record 139:32–35
    [Google Scholar]
  28. Truyen U., Müller T., Heidrich R., Tackmann K., Carmichael L. E. 1998; Survey on viral pathogens in wild red foxes ( Vulpes vulpes ) in Germany with emphasis on parvoviruses and analysis of a DNA sequence from a red fox parvovirus. Epidemiology and Infection 121:433–440
    [Google Scholar]
  29. Von Seggern D. J., Nemerow G. R. 1999; Adenoviral vectors for protein expression. In Gene Expression Systems: Using Nature for the Art of Expression. pp 111–156 Edited by Fernandez J. M., Hoeffler J. P. San Diego: Academic Press;
  30. Vos A., Müller T., Schuster P., Schlüter H., Neubert A. 2000; Oral vaccination of foxes against rabies with SAD B19 in Europe, 1983–1998: a review. Veterinary Bulletin 70:1–6
    [Google Scholar]
  31. Walters R. W., Grunst T., Bergelson J. M., Finberg R. W., Welsh M. J., Zabner J. 1999; Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. Journal of Biological Chemistry 274:10219–10226
    [Google Scholar]
  32. Wandeler A. I. 2000; Oral immunization against rabies: afterthoughts and foresight. Schweizer Archiv für Tierheilkunde 142:455–462
    [Google Scholar]
  33. Wang Y., Xiang Z., Pasquini S., Ertl H. C. J. 1997; The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. Journal of Virology 71:3677–3683
    [Google Scholar]
  34. Xiang Z., Ertl H. C. J. 1999; Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine 17:2003–2008
    [Google Scholar]
  35. Xiang Z. Q., Yang Y., Wilson J. M., Ertl H. C. J. 1996; A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219:220–227
    [Google Scholar]
  36. Yamamoto S., Omura M., Hirata H. 1985; Isolation of porcine, canine and feline IgG by affinity chromatography using protein A. Veterinary Immunology and Immunopathology 5:195–200
    [Google Scholar]
  37. Yarosh O. K., Wandeler A. I., Graham F. L., Campbell J. B., Prevec L. 1996; Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 14:1257–1264
    [Google Scholar]
  38. Zabner J., Freimuth P., Puga A., Fabrega A., Welsh M. J. 1997; Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. Journal of Clinical Investigation 100:1144–1149
    [Google Scholar]
  39. Zöfel P. 1988 Statistik in der Praxis. 2. Auflage Stuttgart: Gustav Fischer;
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-82-9-2191
Loading
/content/journal/jgv/10.1099/0022-1317-82-9-2191
Loading

Data & Media loading...

Most cited Most Cited RSS feed